

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: PharmaDrug Inc. ("PharmaDrug" or the "Issuer").

Trading Symbol: PHRX

Number of Outstanding Listed Securities: 134,214,380

Date: June 4, 2026 for the month ended May 31, 2026

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the month of May, the Issuer continued its normal corporate and administrative operations. On May 13, 2026, the Issuer announced that its subsidiary Sairiyo Therapeutics Inc. is pursuing plans to evaluate its patented enteric-coated oral Cepharanthine formulation (PD-001) as a potential therapeutic candidate for Hantavirus, supported by independent published research identifying cepharanthine as a potential Hantavirus entry inhibitor. Management reviewed the Issuer's activities during the reporting period and confirms that, except as disclosed in this report, there were no other material developments or changes in the business, operations, or affairs of the Issuer that required disclosure during the month.

2. Provide a general overview and discussion of the activities of management.

Management continued to focus on general corporate and administrative matters, including advancing Sairiyo Therapeutics' evaluation of PD-001 for Hantavirus.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

On May 13, 2026, Sairiyo Therapeutics Inc. ("Sairiyo"), a company 51% owned by PharmaDrug, announced plans to evaluate its patented enteric-coated oral Cepharanthine formulation (PD-001) as a potential therapeutic candidate for Hantavirus. The announcement was supported by independent published research identifying cepharanthine as a potential Hantavirus entry inhibitor, including demonstrated inhibition of Hantavirus pseudovirus infection of approximately 94% at 180 mg/kg/day in a mouse model. Sairiyo has previously received approval from an Australian Human Research Ethics Committee to initiate a first-in-human Phase 1 clinical study of PD-001 for viral infectious diseases.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None noted.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None noted.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None noted.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None noted

8. Describe the acquisition of new customers or loss of customers.

None noted.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None noted.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None noted.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None noted.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None noted.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms

of such indebtedness.

None noted.

14. Provide details of any securities issued and options or warrants granted.

None.

15. Provide details of any loans to or by Related Persons.

None noted.

16. Provide details of any changes in directors, officers or committee members.

No changes.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

For more information related to certain risks and uncertainties that are inherent to the Issuer's industry, please refer to the "Risk Factors" section of the Management's Discussion and Analysis filed quarterly on SEDAR.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 4, 2026.

Kyle Appleby
Name of Director or Senior Officer

"Kyle Appleby"
Signature

Chief Financial Officer
Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer PharmaDrug Inc.		May 31, 2026	YY/MM/DD 26/06/04
Issuer Address 77 King Street West, Suite 2905			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
Toronto/ Ontario/ M5K 1H1	()	(647) 202-1824	
Contact Name	Contact Position	Contact Telephone No.	
Kyle Appleby	CFO	(647) 660-8703	
Contact Email Address kappleby@cfoadvantage.ca	Web Site Address www.PharmaDrug.com		